HomeCompareNXTP vs ABBV

NXTP vs ABBV: Dividend Comparison 2026

NXTP yields 1000000.00% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 NXTP wins by $4.7683925249533696e+36M in total portfolio value
10 years
NXTP
NXTP
● Live price
1000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.7683925249533696e+36M
Annual income
$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00
Full NXTP calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — NXTP vs ABBV

📍 NXTP pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodNXTPABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, NXTP + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
NXTP pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

NXTP
Annual income on $10K today (after 15% tax)
$85,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, NXTP beats the other by $4,052,336,490,287,657,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of NXTP + ABBV for your $10,000?

NXTP: 50%ABBV: 50%
100% ABBV50/50100% NXTP
Portfolio after 10yr
$2.3841962624766848e+36M
Annual income
$2,383,727,347,228,033,600,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

NXTP
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
-1.3
Piotroski
3/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

NXTP buys
0
ABBV buys
0
No recent congressional trades found for NXTP or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricNXTPABBV
Forward yield1000000.00%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$4.7683925249533696e+36M$102.3K
Annual income after 10y$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$24,771.77
Total dividends collected$4.7683311610149396e+36M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: NXTP vs ABBV ($10,000, DRIP)

YearNXTP PortfolioNXTP Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$100,010,700$100,000,000.00$11,550$430.00+$100.00MNXTP
2$934,786,450,701$934,679,439,252.34$13,472$627.96+$934786.44MNXTP
3$8,165,787,108,578,292$8,164,786,887,076,042.00$15,906$926.08+$8165787108.56MNXTP
4$66,665,884,190,957,650,000$66,657,146,798,751,470,000.00$19,071$1,382.55+$66665884190957.63MNXTP
5$508,662,171,058,048,100,000,000$508,590,838,561,963,700,000,000.00$23,302$2,095.81+$508662171058048128.00MNXTP
6$3,627,235,248,428,489,700,000,000,000$3,626,690,979,905,457,600,000,000,000.00$29,150$3,237.93+$3.62723524842849e+21MNXTP
7$24,173,681,159,150,610,000,000,000,000,000$24,169,800,017,434,790,000,000,000,000,000.00$37,536$5,121.41+$2.417368115915061e+25MNXTP
8$150,567,402,861,454,640,000,000,000,000,000,000$150,541,537,022,614,370,000,000,000,000,000,000.00$50,079$8,338.38+$1.5056740286145463e+29MNXTP
9$876,477,100,281,847,600,000,000,000,000,000,000,000$876,315,993,160,785,800,000,000,000,000,000,000,000.00$69,753$14,065.80+$8.764771002818475e+32MNXTP
10$4,768,392,524,953,369,600,000,000,000,000,000,000,000,000$4,767,454,694,456,067,000,000,000,000,000,000,000,000,000.00$102,337$24,771.77+$4.7683925249533696e+36MNXTP

NXTP vs ABBV: Complete Analysis 2026

NXTPStock

NextPlay Technologies, Inc., a technology solutions company, provides games, in-game advertising, digital asset products and services, connected TV, and travel booking services to consumers and corporations in the United States, Puerto Rico, Europe, and Thailand. The company operates through three segments: Media, FinTech, and Travel. The Media segment provides HotPlay games studio, a game development studio that develops a range of casual games; HotPlay redemption mobile application, a digital wallet that is used to collect the HotPlay IGA rewards; HotPlay In game advertising and rewards platform, that enable advertisements and rewards to be inserted in game; goPlay platform, a gamification platform for users to compete against each other through tournaments and challenges, as well as a reward platform that rewards users for their continued loyalty and continuous game; and Zappware, a TV as a Service platform, which includes media source ingest, encoding and transcoding, packaging, protection, delivery, playback, and analytics that provide telco operators for their digital media processing, as well as a client side set top box and smart TV middleware platform, associated application framework and corresponding, and supporting content management system. The FinTech segment engages in the development of NextFinTech Platform, an integrated digital financial platform, which offers mobile banking, investments into alternative assets, and insurance to businesses and individuals. The Travel segment offers booking solutions for business and leisure; and travel technology solutions comprising alternative lodging rental properties under NextTrip ConNextions brand. The company was incorporated in 2005 and is based in Sunrise, Florida.

Full NXTP Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this NXTP vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

NXTP vs SCHDNXTP vs JEPINXTP vs ONXTP vs KONXTP vs MAINNXTP vs JNJNXTP vs MRKNXTP vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.